Abstract PS1-05-02: Efbemalenograstim alfa significantly reduces incidence of incidence of severe chemotherapy-induced neutropenia in later cycles: Results of a meta analysis
Abstract
Abstract Introduction: Efbemalenograstim alfa, a non-PEGylated, long-acting, human granulocyte-colony stimulating factor was recently evaluated for the management of chemotherapy-induced neutropenia in a phase III trial of 393 patients with stage I-III invasive breast cancer. The study met the primary end point, demonstrating that a single dose of efbemalenograstim alfa was noninferior to pegfilgrastim, decreasing the duration of severe neutropenia in cycle 1. An additional endpoint of the phase III trial was the incidence of severe neutropenia (ISN; grade 4, ANC
Fields of Study & Subjects
Neutropenia and Cancer Infections
Blood disorders and treatments
Cancer Treatment and Pharmacology
Publication details
- Journal / source
- Clinical Cancer Research
- Volume
- 32
- Issue
- 4_Supplement
- Pages
- PS1–05
- Publication date
- 17 February 2026
- Language
- EN